anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.

The phase II trial included female patients with histologically confirmed stage IIA to IIIC and HER2-positive primary invasive breast cancer. Eligible patients received inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen every three weeks for a maximum of 6 cycles, followed by surgery. The primary endpoint was pathologic complete response (pCR; ypT0 ypN0) rate. Key secondary endpoints included near pCR (npCR) (residual breast disease \<1cm), objective response rate (ORR) and safety. Efficacy was analyzed in the intention-to-treat (ITT) and per-protocol (PP) populations. The ITT population included patients who received at least 2 cycles of the study drug but excluded those who were lost to follow-up without surgery and those who received other targeted therapy. The PP population was a subgroup of patients who met all the trial criteria, were compliant with the protocol, and did not violate any major protocols. Safety was analyzed in the safety population, which included all patients who received at least one dose of the study drug and had available safety data. Fisher's exact test was used for the comparisons between patients with pCR and those with non-pCR.
An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
AIM: Local excision (LE) in selected cases after neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer in clinically complete or major responders has been recently reported as an alternative to standard radical resection. Completion total mesorectal excision (cTME) is generally performed when high-risk pathological features are found in LE surgical specimens. The aim of this study was to evaluate the incidence of residual tumour and lymph node metastases after cTME in patients previously treated by RCT + LE. The secondary aims were to quantify the rate of postoperative morbidity and mortality and to evaluate the long-term oncological outcome of this group of patients.
METHODS: All patients treated from 2007 to 2020 by LE for locally advanced rectal cancer with a clinically complete or major response to RCT who had a subsequent cTME for high-risk pathological factors (ypT >1 and/or TRG >2 and/or positive margins) were included in this multicentre retrospective study. Pathological data, postoperative short-term morbidity (classified according to Clavien-Dindo) and mortality and oncological long-term outcome after cTME were recorded in a database. Statistical analysis was performed using Wizard for iOS version 1.9.31.
RESULTS: A total of 47 patients were included in the study. The rate of R0 resection was 95.7%, and a sphincter-saving procedure was performed in 37 patients (78.7%), with a protective stoma rate of 78.4%. In 28 cases (59.6%), it was possible to perform a minimally invasive approach. A residual tumour (pT and/or pN) on cTME specimens was found in 21 cases (44.7%). The rate of lymph node metastases was 12.8%. The overall short-term (within 30 days) postoperative morbidity was 34%, but grade >2 postoperative complications occurred in only nine patients (19.1%), with a reoperation rate of 6.4%. No short-term postoperative deaths occurred. At a median follow-up of 57 months (range: 21-174), the long-term stoma-free rate was 70.2%, and the actuarial 5-year overall survival (OS), disease-free survival (DFS) and local control (LC) were 86.7%, 88.9% and 95.7%, respectively.
CONCLUSION: When patients exhibit high-risk pathological factors after RCT + LE, cTME should be suggested due to the high risk of residual tumour or lymph node involvement (44.7%). The results after cTME in terms of the rate of R0 resection, sphincter-saving procedure, postoperative morbidity and mortality and long-term oncological outcome seem to be acceptable and do not represent a contraindication to use LE as a first-step treatment in patients with major or complete clinical response after RCT.
Progressive Supranuclear Palsy (PSP) is typically manifested by a multitude of distressing symptoms, including bradyphrenia and bradykinesia, speech dyspraxia, visual problems, and postural instability with high risk of falls. These symptoms not only inflict physical hardships on patients but also have profound emotional and psychological implications. Thus, a decline in self-esteem, a reduction in the quality of life, and heightened stress for caregivers is remarkable. In recent years, art therapy has garnered attention as a potentially effective intervention for individuals grappling with neurodegenerative disorders. Art therapy encompasses a wide array of activities that promote cognitive and motor skills, including shape recognition, motion perception, sensory-motor integration, abstraction, and eye-hand coordination. As a result, it holds promise as a therapeutic tool for addressing the intricate challenges faced by PSP people. Although art therapy has demonstrated positive outcomes in enhancing visual cognitive skills, refining visual exploration strategies, and bolstering general motor function in Parkinson's disease, its potential in the context of PSP remains largely unexplored. Given the unique symptomatology and emotional toll of PSP, patients suffering from this condition stand to benefit significantly from the healing and therapeutic effects of art therapy. In light of these considerations, our proposal aims to bridge this knowledge gap by implementing and rigorously studying the impact of art therapy on PSP patients. Our aim is to investigate the effect of art therapy for people with PSP, with a focus on alleviating the symptoms associated with PSP, enhancing the overall quality of life for patients, and reducing caregiver stress. Overall, through our collaborative efforts on this study, we hope to unlock the benefits of art therapy for this vulnerable patient population, ultimately improving their overall well-being and enhancing their quality of life.
PURPOSE:The titled composition useful as an inhibitor of blood platelet aggregation, hyptotensor, etc. having higher action than existing PG, suitable as a pharmaceutical preparation for oral medication, having extremely improved stability, obtained by dissolving a 7-thiaprostaglandin E1 in a vegetable oil. CONSTITUTION:At least one 7-thiaprostaglandin E1 shown by the formula (R<1> is H, or lower alkyl; R<2> is H, or CH3; R<3> is 5-8C alkyl, or cycloalkyl; broken line shows single bond or double bond) is dissolved in a vegetable oil, to give the titled composition having improved stability. Especially a coconut oil or fractionated coconut oil is preferable as the vegetable oil, and an amount of it used is 100-200,000 times as heavy as the compound shown by the formula. By dissolving the compound in the vegetable oil, stability to acid, alkali, light rays, heat, oxygen, etc. is extremely improved.
OBJECTIVE: The aim of this study was to investigate adverse events related to the administration of Covishield vaccine from the AstraZeneca laboratory in volunteers vaccinated at the Dermatology Hospital of Bamako.
METHODOLOGY: This was a Phase IV clinical trial involving volunteers vaccinated at the Dermatology Hospital of Bamako from April to June 2021. Scientific and ethical aspects were reviewed and addressed. The proposal for this study was approved by the scientific committee of the Hôpital de Dermatologie de Bamako.
RESULTS: A total of 1099 volunteers were included in the study. The median age of participants was 48 years (18-93 years) with a sex ratio of 1.81 (708/391). In all 90.2% of the 1219 adverse events were injection-site pain. Other adverse events were headache, tiredness, and muscle pain, with 3.2% (39/1219), 2.4% (29/1219) and 1.8% (22/1219) respectively. Only one case of diarrhea was reported, 0.08% (1/1219).
CONCLUSION: Adverse events to this vaccine were mostly moderate and temporary but vary according to the population vaccinated individuals.
PURPOSE:To provide a container contg. a transfusion being useful when the transfusion contg. sugars, amino acids, electrolytes and a fatty emulsifying agent is prepd. CONSTITUTION:The objective container 1 has two individual rooms formed by means of a dividing device 7 and transfusion 4 contg. a fatty emulsifying agent and sugars is stored in the first room 2 and a transfusion 5 contg. amino acids and electrolytes is stored in the second room 3. When it is used, a transfusion contg. completed by containing the sugars, the amino acids, the electrolytes and the fatty emulsifying agent is prepd. easily and aseptically by removing the device 7 and mixing the transfusions stored in the first room 2 and the second room 3.
An artificial intelligence system for generating zoological instruction sets from biological extractions. The system includes a computing device, configured to retrieve a biological extraction pertaining to an animal. The computing device is further configured to generate a zoological classifier wherein the zoological classifier utilizes a biological extraction as an input and outputs a zoological profile. The computing device is further configured to receive a zoological input from a remote device, wherein the zoological input identifies a zoological habit. The computing device is further configured to select a zoological machine-learning model utilizing a zoological input, wherein the zoological machine-learning model utilizes a zoological profile as an input and outputs a zoological instruction set. The computing device is further configured to calculate a zoological instruction set utilizing a zoological machine-learning model.
Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
PURPOSE:An anti-inflammatory agent, containing dolichol and/or ester thereof as an active constituent, having mold anti-inflammatory action with slight side effect and useful particularly for treating inflammation of persons, e.g. aged people, or patients with serious diseases, etc. CONSTITUTION:An anti-inflammatory agent containing dolichol expressed by formula I (group expressed by formula II is trans-isoprene unit; group expressed by formula III is cis-isoprene unit; n is an integer 12-18) as an active constituent. The compound expressed by formula I is capable of inhibiting carrageenan induced edema in 300-600mg/kg dose depending on the dose. The agent has low toxicity without side effect of the conventional anti-inflammatory agents, etc. The above-mentioned agent is administered in the dosage form suitable for oral and injection administration, e.g. tablet, capsule, ampul, etc. The compound expressed by formula I can be synthesized from ginkgo and Himalayan ceder purely in large amount according to the method for extraction from internal organs of mammals or the method described in Patent Publication No.58-83643.
Testicular ischemia-reperfusion induces enhanced concentration of reactive oxygen species. The increased reactive oxygen species harm cellular lipids, nucleic acids, proteins, and carbohydrates, and ultimately cause testicular injury. Sulforaphane, a kind of natural dietary isothiocyanate, exists predominantly in some cruciferous vegetables, like broccoli and cabbage. It can protect tissues from oxidative stress-induced damage. Herein, we analyzed the effectiveness of sulforaphane in treating ischemia-reperfusion injury occurring after testicular torsion-detorsion. Male rats (n = 60) were grouped as follows: sham-operated group, unilateral testicular ischemia-reperfusion group, and unilateral testicular ischemia-reperfusion group receiving sulforaphane treatment at 5 mg/kg. No testicular torsion-detorsion was performed in the sham group. Unilateral testicular ischemia-reperfusion model was created by detorsion after 2 h of left testicular torsion. In the sulforaphane-treated group, intraperitoneal sulforaphane (5 mg/kg) was administered at left testicular detorsion. Biochemical assay, Western blot, and hematoxylin and eosin staining were used to evaluate testicular malondialdehyde content (an important marker of reactive oxygen species), protein levels of superoxide dismutase and catalase (intracellular antioxidant defense mechanism), and testicular reproductive function, respectively. In testicular tissues, malondialdehyde content was significantly promoted, while protein levels of superoxide dismutase and catalase, and testicular reproductive function were significantly reduced in ipsilateral testes by testicular ischemia-reperfusion. Nevertheless, sulforaphane administration partially reversed the effect of testicular ischemia-reperfusion on these indexes. It can be concluded that sulforaphane elevates protein levels of superoxide dismutase and catalase, and suppresses reactive oxygen species content, thereby preventing ischemia-reperfusion injury in testis.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, genetic engineering, biochemistry, medicine, veterinary medicine. Synthetic DNA sequence corresponding to gene encoding the protein sequence of the heparin-binding domain (HBD) from Danio rerio fused with human erythropoietin (Epo) sequence (HBD-Epo protein) that nucleotide composition of the codons is optimized for heterologous expression in the non-pathogenic laboratory strain of E. coli. This synthetic HBD-Epo gene is flanked by 5'-end of the NcoI site, and 3'-end site of Kpn2I and inserted into plasmid pQE6 at the NcoI and Kpn2I sites. Based on this, a recombinant plasmid pL610 is obtained containing an artificial bacterial operon of the recombinant HBD-Epo protein comprising the promoter region of the early promoter of bacteriophage T5, the recombinant HBD-Epo protein gene, the transcription terminator; bacterial operon beta-lactamase; a bacterial region of the initiation of replication of the ColE1 type encoding the recombinant HBD-Epo protein and providing its synthesis in E. coli strains. Invention also includes a method for purifying the HBD-Epo protein by ion exchange chromatography. Invention relates to HBD-Epo recombinant protein itself, the expression vector pL610 and the composition (demineralized bone matrix (DCM) containing the HBD-Epo protein, as well as a DCM containing the protein HBD-Epo and BMP-2), aimed at stimulating osteogenesis. Invention allows to obtain a stable purified active protein HBD-Epo, as well as HBD-Epo, immobilized on DCM, including DCM with BMP-2 bone morphogenetic protein.EFFECT: invention further includes a method for specifically inducing bone regeneration, comprising filling the defects of bone tissue with a composition consisting of HBD-Epo immobilized on DCM, including on the DCM with bone morphogenetic protein BMP-2.7 cl, 4 dwg, 5 ex
The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
Pre-oxygenation is a fundamental element of the induction sequence in anesthesia, described and recommended since 1955. Numerous studies have examined and compared the various techniques for implementing this procedure in terms of duration, objectives, equipment, patient characteristics and conditions. None of them specifies who should hold the mask when carrying out this recommendation. In everyday practice, patients are often asked to hold the mask themselves. A preliminary survey showed that 86% of patients are offered this option. The professionals questioned cited relational reasons (83%) above all, but also organizational reasons (43%).
The assessment of pain in patient hospitalized in intensive care remains a challenge, especially for patients which are unable to communicate their pain intensity. Self-reported scales are widely used for children's pain assessment but cannot be used in sedated or non-communicable patients. The gold standard for pain evaluation in sedated-ventilated patient in pediatric intensive care unit is the Comfort Behaviour Scale (CBS). However, this method remains subjective, depending on training and ability to use this clinical tool by the examiner. The Newborn Infant Parasympathetic Evaluation (NIPE) is a non-invasive system based on the analysis variability in high frequency (\> 0.15 Hz) which reflects the parasympathetic activity related to respiratory fluctuations of heart rate. With a numerical index ranging from 0 to 100, NIPE values, measured continuously, has been developed to evaluate the degree of pain intensity. In this study, the hypothese is the NIPE could be used as an indicator of pain in sedated/intubated children under 3 years-old hospitalized in Pediatric intensive care unit.

This study did not change the procedure of care before or after and had no impact on care.
Cedar pollen is known as a typical allergen that causes various allergic symptoms in the nasal mucosa, conjunctiva, and skin. However, inflammation of the vulvar mucosa due to sensitization to cedar pollen is not well-known. We experienced two cases in which the detection of cedar pollen during microscopic urine sediment examination led to the diagnosis of allergic vulvovaginitis caused by cedar pollen. The cases involved a 4-year-old girl and a 10-year-old girl. In both cases, the patients presented with chief complaints of pruritis in the vulva and insomnia due to frequent urination during the season of cedar pollen dissemination. Both patients were afebrile. No inflammatory skin changes such as erythema, swelling, or non-purulent discharge from mucous membranes of the vulva were observed. Microscopic urine sediment examination revealed large amounts of shed cedar pollen. The patients' conditions improved after treatment with oral antihistamines and instruction to dry their underwear indoors. Follow-up blood tests revealed high levels of specific anti-IgE antibodies to cedar pollen, thus confirming a diagnosis of allergic vulvovaginitis due to cedar pollen. Cedar pollen can cause allergic vulvovaginitis. Microscopic urine sediment examination is useful, and when combined with specific IgE antibody testing, leads to an appropriate diagnosis. This disease should also be considered in patients with complaints of vulvar discomfort during the season of cedar pollen dissemination.
Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
A dual channel spray gun, and method of use thereof, for fabricating nanostructures including a pharmaceutical/therapeutic agent having enhanced oral bioavailability. The nanostructures are a mixture of at least two (2) solutions/media substantially equally distributed as desired. The spray gun device uses gas pressure and/or two ultrasonicators to simultaneously prepare two solution systems for subsequent mixture and atomization. The gas pressure and frequencies of the ultrasonicators are adjustable for each channel of the spray gun. In operation, the spray gun is used to prepare microstructures that, for example, contain at least one active pharmaceutical agent in one solution system and excipients, such as coating or bioadhesives, in the other solution system. Any combination of solution systems is contemplated, such as both systems containing a pharmaceutical agent or both systems containing excipients.
Community acquired pneumonia is the cause of morbidity and mortality in children worldwide ,complication of Community acquired pneumonia in paedatrics include para -pneumonic pleural effusion ,empyema, necrotizing pneumonia and lung abscess.( Sawicki GS,2008) Pediatric para-pneumonic pleural effusion and empyema are considered different stages of the same pathophysiological process in which pleural inflammation causes fluid to accumulate in the pleural cavity, Necrotizing pneumonia results from pulmonary necrosis and tissue liquefaction. ( Ira Erlichman, MD,2017) Recent reports have characterized the clinical presentation of this complication and have shown favorable outcomes in children.( Sawicki GS,2008) Complicated pneumonia was defined as clinical pneumonia and the presence of pleural effusion, empyema (EMP) or Para-pneumonic childhood EMP was defined as the presence of pus (purulent fluid and/or WBC count\>5,000 permm3) or bacteria in the pleural fluid.

PPE was defined by pleural fluid not fitting criteria of EMP and the diagnosis of NP was made by the presence of multiple cavity gas-filled spaces within a pulmonary consolidation on chest X-rays or liquefaction of lung tissue according to CT scans as reviewed by a pediatric radiologist .( Ira Erlichman, MD 2017) Among patients with pneumonia AS MANY AS half may develop pleural effusions (i.e., fluid in THE PLEURAL SPACE); of these, 5-10 % MAY DEVELOP EMPYEMAN Ingeneral , "complicated pneumonia" refers to pneumonia accompanied by pleural effusion.( Byington CL,2010) Empyema is a serious COMPLICATIO characterized by pus and bacteria in the pleural space which may progress to necrosis, cavitation, or fistulas in the thoracic cavity. S. pneumoniae is the most common cause of complicated pneumonia in children (an M. A. Fletcher ETT 2014) Empyema among children age below 19 years in Utah (USA) (1994-2007)\] and Australia(1998-2010)ranged from 0.9 to 12.5 per 100,000 (Byington CL,2010)the incidence was highest in children aged 0-4 and tend to increase over time. (Strachan RE,2013).